1. Procedural Biomechanics: Full-Thickness Suturing vs. Staple Line Resection
Endoscopic Sleeve Gastroplasty (ESG) is an organ-sparing, incisionless procedure performed transorally under general anesthesia. Using an endoscopic suturing system (such as Apollo OverStitch), the gastroenterologist places full-thickness, cinch-locked sutures along the greater curvature of the stomach, plicating the tissue into an accordioned gastric tube.
In contrast, Laparoscopic Sleeve Gastrectomy (LSG) is a minimally invasive surgical procedure that permanently resects 75–80% of the stomach using laparoscopic tri-staple technology over a calibration bougie. While ESG creates volumetric restriction via internal tissue folding without removing stomach tissue, LSG achieves structural volumetric reduction alongside permanent tissue excision.
2. Neuroendocrine Shifts: The Ghrelin Fundus Resection Advantage
A fundamental clinical distinction between ESG and LSG lies in neuroendocrine modulation. The gastric fundus contains the highest concentration of parietal ghrelin-producing cells responsible for driving central appetite signals.
Because ESG folds and cinches the gastric cavity internally, the fundus remains anatomically intact inside the body, preserving baseline ghrelin production capacity. Conversely, LSG completely removes the fundus during tissue resection, resulting in an immediate 70–80% drop in circulating serum ghrelin levels that persists for years, providing patients with deep, sustained physiological hunger suppression.
3. Clinical Trial Metrics: EWL % Comparison Matrix
Data from the landmark MERIT Trial (Gastrointestinal Endoscopy) and comparative meta-analyses demonstrate distinct weight loss trajectories and durability profiles between endoscopic suturing and laparoscopic surgery.
Endoscopic Sleeve Gastroplasty (ESG)
Incisionless Transoral Full-Thickness Suturing
Laparoscopic Sleeve Gastrectomy (LSG)
Anatomical Surgical Resection & Fundus Removal
Journey with Confidence
Your health and well-being are our priority. Experience world-class medical excellence while exploring the wonders of Istanbul.
Acıbadem Hospitals Group:
Global Excellence in Healthcare
While you immerse yourself in the rich history of Istanbul, your well-being is protected by a future-focused healthcare leader. Acıbadem provides world-class medical services, from comprehensive health screenings to advanced treatments, all delivered with a commitment to your safety and comfort.
Travel with the assurance that you and your loved ones are in the most capable hands.
4. Recovery Timelines, Inpatient Stays, and Perioperative Complications
Safety parameters and recovery timelines vary based on procedural invasiveness:
ESG Profile: Performed as an outpatient or 1-night observation procedure. Because there are no abdominal skin incisions or intestinal staple lines, risk of staple leaks is eliminated. Primary post-procedure symptoms consist of transient epigastric cramping and nausea, resolving within 48–72 hours.
LSG Profile: Requires a 2-to-3-night inpatient hospital stay in accredited Turkish centers for continuous leak testing, drain monitoring, and IV hydration. While carries a low staple line complication risk (<1% in high-volume hubs), LSG delivers substantially higher metabolic remission for co-morbidities like Type 2 Diabetes and severe fatty liver disease.
5. Candidate Selection Protocols in Turkish Bariatric Centers
Bariatric multi-disciplinary boards in Turkiye utilize strict clinical parameters to recommend between ESG and LSG:
- Ideal ESG Candidates: Patients with Class 1 or Class 2 Obesity (BMI 30–35 kg/m²) who do not qualify for surgical resections under national guidelines, or patients seeking a non-resective, organ-preserving entry point into metabolic intervention.
- Ideal LSG Candidates: Candidates with BMI ≥ 35 kg/m², or BMI 30–34.9 kg/m² presenting with uncontrolled Type 2 Diabetes, severe sleep apnea, or metabolic syndrome, where long-term weight reduction and endocrine ghrelin suppression are clinically required.
While ESG provides a lower-risk option for Class 1 obesity without tissue removal, Laparoscopic Sleeve Gastrectomy achieves ~25% higher Excess Weight Loss at 12 months due to permanent fundal ghrelin elimination.
Enrich Your Exploration
Enhance your medical journey with our hand-picked partners offering luxury stays and seamless travel in Turkiye.
Four Seasons:
Bosphorus, Perfected
Escape the city's vibrant pulse to a serene waterfront palace. Here, timeless elegance and flawless service create your perfect moment.
Garenta:
Discover More of Turkiye
Don't just see the landmarks; experience the real culture. Garenta offers the freedom to discover hidden treasures at your own pace.
Academic References & Data Sources
- Abu Dayyeh, B. K., et al. (MERIT Study Group) (2022): Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity: a randomised multicentre trial. The Lancet, 400(10350), 441–451.
- Sharaiha, R. Z., et al. (2017): Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clinical Gastroenterology and Hepatology, 19(5), 1051–1057.
- Yoon, J. Y., & Arau, R. (2021): Comparative efficacy of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: A systematic review and meta-analysis. Surgical Endoscopy, 35(8), 4089–4102.
- Cheskin, L. J., et al. (2020): Weight loss and metabolic outcomes following bariatric endoscopy versus laparoscopic bariatric surgery. Obesity Surgery, 30(11), 4312–4121.

